How were Angion Biomedica's earnings last quarter?

Angion Biomedica Corp. (NASDAQ:ANGN) posted its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The company earned $1.46 million during the quarter, compared to analysts' expectations of $1.08 million.

When did Angion Biomedica's stock split?

Angion Biomedica's stock reverse split on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Angion Biomedica IPO?

Angion Biomedica (ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ANGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.00
▼
$10.00
52-Week Range: N/A

Volume: 224,800 shs
Average Volume: 86,718 shs
Market Capitalization: $30.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Angion Biomedica alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Angion Biomedica Stock (NASDAQ:ANGN)

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

ANGN Stock News Headlines

June 1, 2023 | finance.yahoo.com

Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

May 2, 2023 | marketwatch.com

8-K: Angion Biomedica Corp.

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 27, 2023 | finance.yahoo.com

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

April 11, 2023 | markets.businessinsider.com

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVA

April 6, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, ANGN, TIG

March 4, 2023 | stockhouse.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLI, DCT, ANGN

February 24, 2023 | stockhouse.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, OSH, IAA

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

January 22, 2023 | benzinga.com

Moore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law Firm

January 18, 2023 | benzinga.com

STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGN

January 17, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. Merger

January 17, 2023 | marketwatch.com

Angion Biomedica Shares Tumble Premarket on Elicio Tie-Up >ANGN

January 17, 2023 | technews.tmcnet.com

ANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to Shareholders

December 27, 2022 | finance.yahoo.com

Bullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)

December 22, 2022 | finanznachrichten.de

Angion Biomedica Corp.: Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

December 22, 2022 | finance.yahoo.com

Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

November 29, 2022 | nasdaq.com

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

November 29, 2022 | nasdaq.com

Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

November 24, 2022 | msn.com

Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

November 17, 2022 | nasdaq.com

Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How

November 10, 2022 | finance.yahoo.com

Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales

November 4, 2022 | finance.yahoo.com

Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss

November 1, 2022 | finance.yahoo.com

Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View

October 13, 2022 | finance.yahoo.com

Is Angion Biomedica (NASDAQ:ANGN) In A Good Position To Deliver On Growth Plans?

September 24, 2022 | finance.yahoo.com

Angion Biomedica Corp. (ANGN)

September 12, 2022 | msn.com

Angion Biomedica's Return On Capital Employed Overview

See More Headlines

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ANGN
CUSIP: N/A
CIK: 1601485
Web: www.angion.com
Phone: 415-655-4899
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,810,000.00
Net Margins: N/A
Pretax Margin: -4,456.97%
Return on Equity: -47.53%
Return on Assets: -40.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.00
Quick Ratio: 20.00

Sales & Book Value

Annual Sales: $2.30 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.32 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 30,110,000
Free Float: 24,182,000
Market Cap: $30.11 million
Optionable: Not Optionable
Beta: 0.60

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Jay R. Venkatesan M.B.A. (Age 51)
M.D., Ph.D., Pres, CEO & Chairman
Comp: $619.88k
Ms. Jennifer J. Rhodes J.D. (Age 53)
Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.
Comp: $453.04k
Mr. Gregory S. Curhan (Age 61)
Chief Financial Officer
Mr. Daniel Iazzetti
VP of HR

Key Competitors

View All Competitors

ANGN Stock Analysis - Frequently Asked Questions

How were Angion Biomedica's earnings last quarter?: Angion Biomedica Corp. (NASDAQ:ANGN) posted its quarterly earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The company earned $1.46 million during the quarter, compared to analysts' expectations of $1.08 million.
When did Angion Biomedica's stock split?: Angion Biomedica's stock reverse split on Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
When did Angion Biomedica IPO?: Angion Biomedica (ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

This page (NASDAQ:ANGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Angion Biomedica (ANGN) Stock Price, News & Analysis

About Angion Biomedica Stock (NASDAQ:ANGN)

ANGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ANGN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info